Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

Authors

Joshua J. Field, Blood Center of Wisconsin
Elaine Majerus, Washington University School of Medicine in St. Louis
Victor R. Gordeuk, The University of Illinois at Chicago
Michel Gowhari, The University of Illinois at Chicago
Carolyn Hoppe, University of California San Francisco Benioff Children's Hospital
Matthew M. Heeney, Boston Children's Hospital
Maureen Achebe, Brigham and Women's Hospital
Alex George, Texas Children's Hospital
Hillary Chu, Dana-Farber Cancer Institute
Brian Sheehan, Dana-Farber Cancer Institute
Maneka Puligandla, Dana-Farber Cancer Institute
Donna Neuberg, Dana-Farber Cancer Institute
Gene Lin, La Jolla Institute for Allergy and Immunology
Joel Linden, La Jolla Institute for Allergy and Immunology
David G. Nathan, Boston Children's Hospital

Journal

Blood Advances

Publication Date

2017

Volume

1

Issue

20

Inclusive Pages

1645-1649

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2017009613

Rights and Permissions

Field, J. J., Majerus, E., Gordeuk, V. R., Gowhari, M., Hoppe, C., Heeney, M. M., Achebe, M., George, A., Chu, H., Sheehan, B., Puligandla, M., Neuberg, D., Lin, G., Linden, J., & Nathan, D. G. (2017). Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 1(20), 1645-1649. https://doi.org/10.1182/bloodadvances.2017009613.

Recommended Citation

Field, Joshua J.; Majerus, Elaine; Gordeuk, Victor R.; Gowhari, Michel; Hoppe, Carolyn; Heeney, Matthew M.; Achebe, Maureen; George, Alex; Chu, Hillary; Sheehan, Brian; Puligandla, Maneka; Neuberg, Donna; Lin, Gene; Linden, Joel; and Nathan, David G., "Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease." Blood Advances. 1, 20. 1645-1649. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/7238